X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (142) 142
male (107) 107
female (101) 101
oncology (94) 94
index medicus (86) 86
aged (85) 85
middle aged (84) 84
cancer (65) 65
adult (61) 61
chemotherapy (51) 51
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
gastroenterology & hepatology (37) 37
treatment outcome (36) 36
colorectal cancer (34) 34
gastric cancer (32) 32
stomach neoplasms - drug therapy (31) 31
medicine & public health (28) 28
stomach cancer (27) 27
aged, 80 and over (26) 26
care and treatment (26) 26
metastasis (26) 26
oxaliplatin (26) 26
animals (25) 25
prognosis (25) 25
stomach neoplasms - pathology (25) 25
survival (25) 25
analysis (24) 24
fluorouracil (24) 24
survival rate (24) 24
research (23) 23
5-fluorouracil (22) 22
cisplatin (22) 22
gastroenterology and hepatology (21) 21
surgical oncology (21) 21
trial (21) 21
antineoplastic combined chemotherapy protocols - adverse effects (20) 20
camptothecin - analogs & derivatives (20) 20
fluorouracil - administration & dosage (20) 20
japan (20) 20
therapy (20) 20
cancer research (19) 19
colorectal neoplasms - drug therapy (19) 19
disease-free survival (19) 19
cisplatin - administration & dosage (18) 18
clinical trials (18) 18
oncology, experimental (18) 18
original (18) 18
surgery (18) 18
tegafur - administration & dosage (18) 18
drug combinations (17) 17
expression (17) 17
gastroenterology (17) 17
antimitotic agents (16) 16
antineoplastic agents (16) 16
camptothecin - administration & dosage (16) 16
irinotecan (16) 16
leucovorin - administration & dosage (16) 16
organoplatinum compounds - administration & dosage (16) 16
original article (16) 16
retrospective studies (16) 16
cancer patients (15) 15
leucovorin (15) 15
mice (15) 15
neoplasm staging (15) 15
oxonic acid - administration & dosage (15) 15
carcinoma (14) 14
drug administration schedule (14) 14
hepatocellular carcinoma (14) 14
tumors (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
capecitabine (13) 13
medicine, general & internal (13) 13
s-1 (13) 13
adenocarcinoma - drug therapy (12) 12
apoptosis (12) 12
cells (12) 12
internal medicine (12) 12
pharmacology & pharmacy (12) 12
stomach neoplasms - mortality (12) 12
1st-line treatment (11) 11
cancer therapies (11) 11
cell line, tumor (11) 11
colorectal neoplasms - pathology (11) 11
follow-up studies (11) 11
leucovorin - adverse effects (11) 11
liver (11) 11
metastases (11) 11
nutrition & dietetics (11) 11
phase-ii (11) 11
bevacizumab (10) 10
breast-cancer (10) 10
fluorouracil - adverse effects (10) 10
lung neoplasms - secondary (10) 10
medical research (10) 10
prospective studies (10) 10
reactive oxygen species (10) 10
abdominal surgery (9) 9
colorectal neoplasms - mortality (9) 9
fluorouracil - therapeutic use (9) 9
japan - epidemiology (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Clinical Oncology, ISSN 1341-9625, 4/2015, Volume 20, Issue 2, pp. 207 - 239
Journal Article
by Watanabe, Toshiaki and Watanabe, Toshiaki and Itabashi, Michio and Itabashi, Michio and Shimada, Yasuhiro and Shimada, Yasuhiro and Tanaka, Shinji and Tanaka, Shinji and Ito, Yoshinori and Ito, Yoshinori and Ajioka, Yoichi and Ajioka, Yoichi and Hamaguchi, Tetsuya and Hamaguchi, Tetsuya and Hyodo, Ichinosuke and Hyodo, Ichinosuke and Igarashi, Masahiro and Igarashi, Masahiro and Ishida, Hideyuki and Ishida, Hideyuki and Ishiguro, Megumi and Ishiguro, Megumi and Kanemitsu, Yukihide and Kanemitsu, Yukihide and Kokudo, Norihiro and Kokudo, Norihiro and Muro, Kei and Muro, Kei and Ochiai, Atsushi and Ochiai, Atsushi and Oguchi, Masahiko and Oguchi, Masahiko and Ohkura, Yasuo and Ohkura, Yasuo and Saito, Yutaka and Saito, Yutaka and Sakai, Yoshiharu and Sakai, Yoshiharu and Ueno, Hideki and Ueno, Hideki and Yoshino, Takayuki and Yoshino, Takayuki and Fujimori, Takahiro and Fujimori, Takahiro and Koinuma, Nobuo and Koinuma, Nobuo and Morita, Takayuki and Morita, Takayuki and Nishimura, Genichi and Nishimura, Genichi and Sakata, Yuh and Sakata, Yuh and Takahashi, Keiichi and Takahashi, Keiichi and Takiuchi, Hiroya and Takiuchi, Hiroya and Tsuruta, Osamu and Tsuruta, Osamu and Yamaguchi, Toshiharu and Yamaguchi, Toshiharu and Yoshida, Masahiro and Yoshida, Masahiro and Yamaguchi, Naohiko and Yamaguchi, Naohiko and Kotake, Kenjiro and Kotake, Kenjiro and Sugihara, Kenichi and Sugihara, Kenichi and Japanese Soc Canc Colon Rectum and Japanese Society for Cancer of the Colon and Rectum
International Journal of Clinical Oncology, ISSN 1341-9625, 2/2012, Volume 17, Issue 1, pp. 1 - 29
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 35, pp. 4438 - 4444
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1843 - 1850
This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second‐line... 
colorectal cancer | RAS mutation | panitumumab | liquid biopsy | Bevacizumab | 1ST-LINE TREATMENT | LEUCOVORIN | MULTICENTER | DETERMINANTS | PHASE-III | ACQUIRED-RESISTANCE | FLUOROURACIL | TRIAL | CETUXIMAB | ONCOLOGY | 2ND-LINE TREATMENT | ras Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biomarkers, Tumor | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Proto-Oncogene Proteins B-raf | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Retreatment | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Aged | Mutation | Antimitotic agents | Chemotherapy | Endothelial growth factors | Analysis | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Antineoplastic agents | Blood proteins | Cancer | Immunoassay | Colorectal carcinoma | Values | Oncology | Serum proteins | Cancer therapies | K-Ras protein | Metastases | Proteins | Oxaliplatin | Epidermal growth factor | Vascular endothelial growth factor | Deoxyribonucleic acid--DNA | Immunoglobulins | Survival | Patients | Studies | Irinotecan | Biomarkers | Ligands | Original
Journal Article
Journal of Clinical Biochemistry and Nutrition, ISSN 0912-0009, 2011, Volume 48, Issue 2, pp. 107 - 111
Journal Article
Cancer Science, ISSN 1347-9032, 05/2015, Volume 106, Issue 5, pp. 627 - 634
Journal Article